ChemicalBook > Product Catalog >API >Antiallergic drugs >Allergic Reactions >(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid

(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid

Request For Quotation
(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Suppliers list
Company Name: LGM Pharma  
Tel: 1-(800)-881-8210
Email: inquiries@lgmpharma.com
Company Name: Guangzhou Isun Pharmaceutical Co., Ltd  
Tel: 020-39119399 18927568969
Email: isunpharm@qq.com
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Energy Chemical  
Tel: 400-0056266
Email: marketing1@energy-chemical.com

(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid manufacturers

  • Veliflapon
  • Veliflapon pictures
  • $1690.00
  • 2026-04-22
  • CAS:128253-31-6
  • Purity:
  • Supply Ability: 10g
  • Veliflapon
  • Veliflapon pictures
  • $1690.00
  • 2025-08-22
  • CAS:128253-31-6
  • Purity:
  • Supply Ability: 10g
(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Basic information
Product Name:(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid
Synonyms:(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid;2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid;BAY-X 1005;BAY 1005;DG 031;Velifapon;(αR)-α-Cyclopentyl-4-(2-quinolinylmethoxy)-benzeneacetic acid;α-Cyclopentyl-4-(2-quinolinylmethoxy)-(R)-benzeneacetic acid
CAS:128253-31-6
MF:C23H23NO3
MW:361.43
EINECS:
Product Categories:
Mol File:128253-31-6.mol
(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Structure
(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical Properties
Melting point 169-171 °C
Boiling point 555.4±40.0 °C(Predicted)
density 1.242±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: soluble5mg/mL (clear solution)
form powder
pka4.47±0.10(Predicted)
color white to beige
InChI1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)/t22-/m1/s1
InChIKeyZEYYDOLCHFETHQ-JOCHJYFZSA-N
SMILESOC(=O)[C@H](C1CCCC1)c2ccc(OCc3ccc4ccccc4n3)cc2
Safety Information
Hazard Codes Xn
Risk Statements 22
WGK Germany 3
Storage Class11 - Combustible Solids
Hazard ClassificationsAcute Tox. 4 Oral
MSDS Information
(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Usage And Synthesis
UsesPrevention of acute cardiovascular events.
Biological Activitybay-x 1005 is a selective inhibitor of 5-lipoxygenase-activating protein [1].5-lipoxygenase-activating protein (flap) is an integral protein and plays an important role in the activation of 5-lipoxygenase (5-lox) and the synthesis of leukotrienes, which regulating immune responses.bay-x 1005 is a selective inhibitor of leukotriene synthesis. bay x 1005 binds to flap and inhibits 5-lox translocation from the cytosol to membranes [1]. bay-x1005 inhibited ltb4 synthesis with ic50 values of 0.22, 0.026 and 0.039 μm for isolated pmnl of human, rat and mouse respectively and inhibited ltc4 synthesis with ic50 value of 0.021 μm in mouse macrophages [2].in the arachidonate-induced mouse ear inflammation test, bay-x 1005 inhibited myeloperoxidase activity and edema formation with ed50 values of 7.9 and 48.7, respectively [2].also, bay-x 1005 (100 mg/kg) reduced platelet-activating factor-induced death of mice by 51% in a dose-dependent way. in animal models, bay-x 1005 inhibited the synthesis of ltb4 and ltc4, which reduced edema formation, the vascular phenomena of inflammation and leukocyte immigration [3].
in vivo

Veliflapon (BAY X 1005; DG-031; diet; 18.8 mg/kg/day for 16 weeks ) inhibits atherogenesis[4].
Veliflapon after topical (18 μg/ear) and oral (48.7 mg/kg) administration has antiedematous effects in the arachidonic acid-induced mouse ear inflammation test[4].
Veliflapon is potent (11.8 and 6.7 mg/kg p.o. at 1 and 5 hours, respectively) and has a long duration of action (ED40 of 16 hours, 70 mg/kg p.o.) in the rat whole blood ex vivo leukotriene B4 inhibition assay[4].

Animal Model:Female apoE/LDLR-DKO mouse model[4]
Dosage:18.8 mg/kg
Administration:Diet; per day during 16 weeks
Result:Inhibited atherogenesis.
IC 50LTB4; LTC4
references[1]. hatzelmann a, fruchtmann r, mohrs kh, et al. mode of action of the leukotriene synthesis (flap) inhibitor bay x 1005: implications for biological regulation of 5-lipoxygenase. agents actions, 1994, 43(1-2): 64-68.
[2]. müller-peddinghaus r, fruchtmann r, ahr hj, et al. bay x1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. j lipid mediat, 1993, 6(1-3): 245-248.
[3]. müller-peddinghaus r, kohlsdorfer c, theisen-popp p, et al. bay x1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. j pharmacol exp ther, 1993, 267(1): 51-57.
(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Preparation Products And Raw materials
Tag:(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid(128253-31-6) Related Product Information
1005 2-(4-methoxyphenyl)butanoic acid (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid 2-(p-Hydroxyphenyl)isovaleric acid 3-Methyl-2-phenylvaleric acid 4-Ethoxyphenylacetic acid Cyclopentylacetic acid alpha-Phenylcyclopentaneacetic acid